Psychotic Disorders Clinical Trial
Official title:
Be Outspoken and Overcome Stigmatizing Thoughts: A Randomized Controlled Trial Targeting Self-Stigma in First Episode Psychosis
Stigma towards mental illness is one of the greatest barriers to functional recovery that people with psychotic disorders face. Internalization of stigma (self-stigma) is associated with increased depressive symptoms, treatment non-adherence, and reduced quality of life. Self-stigma also has functional consequences, such as social avoidance and decreased help-seeking behaviour, which may worsen symptoms and impede recovery. Despite a growing awareness of the negative outcomes associated with self-stigma, few interventions have been designed to specifically address this experience in first episode psychosis. This project proposes to determine the effectiveness of an innovative, youth-oriented, group-based intervention known as Be Outspoken and Overcome Stigmatizing Thoughts (BOOST), which aims to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
BOOST is a manualized intervention that combines psychoeducation and cognitive restructuring
to replace stigmatizing views about early psychosis and help patients challenge negative
self-evaluations. Assertiveness skills training is a unique component that was added to the
group to empower individuals and provide them with the behavioural skills to fight back
against self-stigma and get their needs met during social interactions.
Sessions are 60 minutes long and occur once a week for 8 weeks. Groups comprise 4-6
outpatients enrolled in a specialized outpatient clinic for early psychosis. Session are led
by one therapist and co-facilitated with a peer support worker who has "lived experience"
with early psychosis to provide unique insights on living with and overcoming self-stigma.
The group format is informal and discussion-based, with an emphasis on sharing personal
experiences.
Early sessions (1-4) focus on dispelling popular myths associated with psychosis and
challenging erroneous beliefs, as a way to provide psychoeducation to patients. Additionally,
time is spent identifying the impact of self-labelling, how this can lead to self-fulfilling
prophecies, and getting participants to reflect on examples of when self-stigma might have
behavioural consequences. Cognitive behavioural therapy techniques are used as a basis for
the intervention, with an initial focus on cognitive restructuring to fight back against
negative, stigmatizing thoughts.
Later sessions (5-8) target behavioural approaches for self-empowerment through assertiveness
skills training and goal setting. Discussions are focused on the verbal and non-verbal
characteristics of passive, aggressive, and assertive communication, in addition to
techniques for speaking in an assertive manner. Role play scenarios that are specific to
young people with psychosis provide opportunities to practice these skills in session. For
example, Speaking up to a psychiatrist about the negative side effects of a medication or
reaching out to a friend for support after returning from a hospitalization.
Weekly "missions" (i.e., home practice activities) are administered following each session to
build on group content and help participants fight back against self-stigmatizing thoughts
and attitudes in everyday contexts.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00253240 -
Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population
|